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Introduction: Elevated DNA-repair capacity has been related to 
chemoresistance of platinum doublet chemotherapy in non–small-cell 
lung cancer (NSCLC). We evaluated whether single nucleotide poly-
morphisms  of DN- repair genes excision repair cross- complementing 
group 1 (ERCC1), ERCC2, x-ray repair cross-complementing group 
1 (XRCC1), XRCC3, and RRM1 associate with treatment outcome in 
NSCLC patients receiving gemcitabine plus platinum as their first-
line chemotherapy.
Methods: Genotyping for eight polymorphisms in five DNA-repair 
genes was performed with the GenomeLab nucleotide polymor-
phismstream Genotyping System in 62 advanced NSCLC patients 
in a training set and 45 patients in a validation set treated with 
gemcitabine/platinum.
Results: In the training set, the wild-type genotype of XRCC1 
Arg399Gln (G/G) was associated with decreased median overall sur-
vival (oS) (22 months, 95% confidence interval [CI], 10–34 months 
versus not reached, log-rank test, p = 0.005) than those carrying variant 
genotypes (G/A+A/A). In addition, there was a statistically significant 
longer median oS in patients carrying wild-type ERCC2 Asp312Asn 
genotype (G/G) (51 months, 95% CI, 19–82 months versus 10 months, 
log-rank test, p < 0.001) than those carrying heterozygous variant 
genotypes (G/A). In the multivariate Cox model, we found a signifi-
cant effect of XRCC1 Arg399Gln (G/A+A/A versus G/G, hazard ratio 
[HR] 0.290; 95%CI, 0.12–0.705, p = 0.006) and ERCC2 Asp312Asn 
(G/A versus G/G, HR 14.04; 95% CI, 2.253–87.513, p = 0.005) poly-
morphisms on patients’ oS. In the validation set, only XRCC1 399 
polymorphisms showed significant effect on patients’ oS (G/A+A/A 
vs. G/G, HR 0.474; 95% CI, 0.245–0.915, p = 0.026)
Conclusions: Genetic polymorphism of XRCC1 Arg399Gln may be 
a candidate for contributing interindividual difference in the oS of 
gemcitabine/platinum-treated advanced NSCLC patients.
Key Words: Non–small-cell lung cancer, DNA repair, Single nucle-
otide polymorphism.
(J Thorac Oncol. 2012;7: 973–981)
Lung cancer is the leading cause of death with regard to can-cer in many countries,1 including Taiwan. About half of the 
newly diagnosed non–small-cell lung cancer (NSCLC) cases 
are already at an advanced stage (stage IIIB and IV), and nearly 
90% of these patients die within 2 years.2 Although molecu-
lar therapy targeting epidermal growth factor receptor (EGFR) 
pathway and vascular endothelial growth factor pathway are 
recently shown to improve patients’ survival to a certain degree,3 
chemotherapy with platinum doublet remains the main treat-
ment modality for advanced lung cancer.4,5 The reality is that 
the response to chemotherapy agents varies widely among and 
within individuals. Hence, the use of molecular predictive mark-
ers to help identify who may benefit and who may not remains 
one of the most exciting new areas of study in oncology.6
Recently, the expression of ERCC1 (excision repair 
cross-complementing group 1), measured by immunohis-
tochemical staining in surgically resected specimen, was shown 
to be associated with poor response to platinum-containing 
adjuvant chemotherapy.7 ERCC1 belongs to a group of genes 
responsible for nucleotide excision repair (NER). Because the 
cytotoxic effect of platinum drugs is attributed to the forma-
tion of bulky platinum-DNA adducts, which block replication 
and inhibit transcription, removal of these adducts from the 
genomic DNA is conducted by the NER system. Cisplatin 
resistance seems to be associated with the increased removal 
of cisplatin-DNA adducts.8 Elevated DNA-repair capacity had 
been related to chemoresistance in NSCLC. ERCC1 plays a 
pivotal role in NER, and there is plenty of evidence to show 
that the level of ERCC1 (either mRNA or protein expression) 
is important for the repair of platinum-DNA adducts and the 
response to platinum-based chemotherapy.9,10 In addition to 
measuring protein and mRNA expression, studies addressed 
to the polymorphism of ERCC1 (118 C/T and C8092A) have 
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also demonstrated its impact on the survival of chemotherapy-
treated NSCLC patients.11,12
Xeroderma pigmentosum group D/excision repair 
cross-complementing group 2 (ERCC2) is an important NER 
protein intervening both the transcription-coupled-NER and 
global genomic-NER subpathways.6 Populations bearing the 
genotype Lys751Lys and Asp312Asp are known to have good 
DNA-repair capacity, whereas those with Gln751Gln and 
Asn312Asn have suboptimal DNA-repair capacity.13 X-ray 
repair cross-complementing group 1 (XRCC1) and X-ray 
repair cross-complementing group 3 (XRCC3 ) are two other 
proteins involving NER, and the polymorphism of these two 
proteins (XRCC1 399 and XRCC3 241) has been recently 
shown to be a prognostic factor of survival.14
Gemcitabine, a deoxycitidine analogue, in combination 
with a platinum drug is a standard regimen for the first-line 
treatment of advanced NSCLC. In addition to being incorpo-
rated into DNA after entering the cell and being phosphory-
lated, gemcitabine exerts its cytotoxic effect by inhibiting the 
DNA-repair mechanism and ribonucleotide reductase.15 The 
synergistic action of gemcitabine and cisplatin is thought to 
reside in an inhibitory effect of gemcitabine on the repair of the 
intrastrand adduct and interstrand cross-link, which are induced 
by cisplatin.16–18 In addition, gemcitabine inhibits ribonucle-
otide reductase, and then depletes the deoxynucleotide pools 
required for DNA repair and replication. As for ribonucleotide 
reductase, most of the studies have been consistently showing 
that low  ribonucleotide reductase subunit M1 (RRM1) mRNA 
expression is associated with significantly longer overall sur-
vival (oS) in gemcitabine-treated patients in NSCLC.19 In 
addition, RRM1 polymorphisms in the promoter region have 
been correlated with outcome in NSCLC patients treated with 
gemcitabine20 and the RRM1 polymorphisms, 2455 A>G and 
2464 G>A, comprise biomarkers of resistance to gemcitabine, 
and correlate with poor oS in breast cancer patients.21
Because of the scarcity of obtaining enough tumor tis-
sue in advanced lung cancer for measuring mRNA expres-
sion, or performing immunohistochemical staining of protein, 
using blood cells is a reasonable substitute for studying pre-
dictive markers of chemotherapy response. one solution is to 
study single nucleotide polymorphisms (SNPs) in blood cells. 
Recently, SNPs have been confirmed as predictive mark-
ers of treatment response, toxicity, and survival of cancer 
patients.22,23 As mentioned previously, two common SNPs of 
ERCC1, codon 118 C/T and C8092A, are well recognized. 
The codon 118 C/T is associated with different mRNA levels, 
whereas C8092A links to RNA stability. Shorter survival was 
reported in C/C genotype of C8092A and C/C genotype of 
codon 118; however, the other studies reported no significant 
association of genotypes with survival or the opposite results.22 
Prognostic implications of SNPs in other DNA-repair genes 
ERCC2, XRCC1, XRCC3, and RRM1 were also inconsistent 
in various small studies.11,23–26 The differences in study design, 
methodology, and reporting of results across studies and eth-
nic-related differences in allele frequencies may result in the 
inconsistent associations with SNPs.
According to the above observations, several SNPs of 
DNA-repair genes may affect the treatment efficacy of plati-
num agents and gemcitabine, and their synergistic effect when 
used in combination. For this study, we evaluated the associa-
tions of eight genetic polymorphisms (ERCC1 Asn118Asn, 
ERCC1 C8092A, ERCC2 Lys751Gln, ERCC2 Asp312Asn, 
XRCC1 Arg399Gln, XRCC3 Thr241Met, RRM1 A2455G, 
and RRM1 G2464A) of five DNA-repair genes with treatment 
response and oS in NSCLC patients receiving gemcitabine 
plus platinum as their first-line chemotherapy.
PATIENTS AND METHODS
Patients
For this study, we enrolled 62 patients as the training 
set. They were histologically diagnosed and staged as clini-
cally advanced (stage IV, or stage IIIB with pleural effusion) 
NSCLC from 2004 through 2008 in both National Taiwan 
University Hospital (NTUH) and Taipei Veterans General 
Hospital (TVGH). All patients were evaluated with computed 
tomography of the brain, thorax, and abdomen before initia-
tion of therapy. Patients with brain metastasis and Eastern 
Cooperative oncology Group performance status more than 
2 were not included. only those who had received or consid-
ered receiving chemotherapy as their first-line treatment were 
eligible for this study. All patients provided written informed 
consent for participation and for the analysis of genetic poly-
morphisms in association with clinical findings. After consent, 
10 ml of the patient’s blood was drawn. Before treatment, all 
patients underwent a complete history and physical examina-
tion, including routine hematology and biochemistry analysis. 
Hematology and biochemistry analyses are repeated before 
the start of each chemotherapy delivery. Age, sex, histological 
type, EGFR mutation status, clinical stage, chemotherapy reg-
imen, and toxicity were recorded. The validation set consisted 
of 45 NSCLC patients, stage IIIB or IV, from an independent 
cohort of patients receiving gemcitabine plus cisplatin as 
their first-line chemotherapy at NTUH or Taichung Veterans 
General Hospital between 2000 and 2004 with available 
genomic DNA for analysis. The study was approved by the 
NTUH Research Ethics Committee, the TVGH Institutional 
Review Board and Institutional Review Board of the Taichung 
Veterans General Hospital.
Chemotherapy and Clinical Response
Patients received gemcitabine 1250 mg/m2 on days 1 and 
8 every 3 weeks in combination with cisplatin 75 mg/m2, car-
boplatin AUC 5 or oxaliplatin 130 mg/m2, both administered 
on day 1 every 3 weeks. Patients might receive bevacizumab at 
a dose of 7.5 or 15 mg/kg on day 1 as per the decision of their 
attending physician. The response of tumor to chemotherapy 
was assessed after three cycles of chemotherapy and every 
three cycles thereafter, using Response Evaluation Criteria in 
Solid Tumor criteria. The best response to first-line chemo-
therapy was reported as complete response, partial response, 
stable disease, or progressive disease (PD). Progression-free 
survival was evaluated for the period from the date of treat-
ment initiation to the date when disease progression was first 
observed or death occurred. oS was calculated from the date 
of cancer diagnosis to the date of the last follow-up (death or 
clinical visit). For this study, the survival data were censored 
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on July 31, 2009, for the training set and on December 31, 
2011, for the validation set.
DNA Extraction and Genotyping
Genomic DNA was extracted from total blood cells 
using QIAamp Blood MiniKit (QIAGEN Inc., Germany) and 
subject to SNP study. The primers for multiplex polymerase 
chain reaction (PCR) and single-base extension primers are 
designed with Web-based software provided at http://www.
autoprimer.com (Beckman Coulter Inc., Fullerton, CA). 
SNP reactions were performed using the method described 
previously27 and analyzed with GenomeLab SNPstream 
Genotyping System (Beckman Coulter Inc.) at the Microarray 
core facility of the NTU Center of Genomic Medicine. For 
multiplex PCR reaction, PCR Buffer, MgCl2 (25mM), dNTP-
mix, primer pool (10μM, containing all interested SNPs with 
same nucleotide transition), AmpliTaq Gold Ò (Applied 
Biosystems Inc., Foster City, CA), and H2o are mixed to 
form PCR master mix. Five μg of genomic DNA and 3 μl of 
PCR master mix are added into each 384-well PCR plate. The 
plate is sealed tightly with sealing film and spin down and 
subjected to PCR reaction with the following thermal cycles. 
(94°C, 1 min; 92°C, 30 sec; 55°C, 30 sec; 72°C, 1 min) for 
34 cycles, then stored in 4°C. The reaction mixture is then 
cleaned up by adding 3 μl clean-up reagent into each well. 
Reaction at 37C for 30 minutes is followed by reaction at 968C 
for 10 minutes. Primer extension is performed by adding 7 
μl primer extension mixture (SNP primer Pool [10 μM each] 
17.5μl, SNPware Extension Mix 115 μl, SNPware Extension 
Mix Dilution Buffer 2126 μl, SNPware DNA polymerase 
12 μl, H
2
o, 1718 μl, total volume 4000 μl) into each well 
of each plate with the following reaction: 96C, 3 minutes; 
948C, 20 seconds; 408C, 11 seconds) for 45 cycles, then stored 
at 48C. After wash with SNPware Wash Buffer, 8 μl of the 
hybridization solution (SNPware Hybridazation Solution) 
is added into each well. After transferring 10 μl of the mix 
from 384 PCR plate to SNPware tag array plate, hybridiza-
tion reaction is carried out by incubating the plate at 428C in 
the humidified covered container in the oven for 2 hours, then 
washed by Tag array with SNPware Wash Buffer II, vacuum 
dried, cleaned, and subjected for imaging by GenomeLab 
SNPstream array imager. Graphic review and operator adjust-
ment of the genotype clusters can be performed to refine fluo-
rescent cutoff value.
Statistical Analysis
Demographic and clinical information was compared 
across genotypes using Pearson’s 2 test. The frequencies of 
different genotypes were compared between patients with 
and without treatment response using the Fisher’s exact test. 
odds ratio (oR) and the 95% confidence intervals (CI) for 
the response (responder versus nonresponder) were calculated 
using the logistic regression model. The association between 
oS and the polymorphisms was estimated by the Kaplan-
Meier method. Comparison of survival curves was accessed 
using log-rank test. Univariate and multivariate hazard ratios 
(HR) were determined using Cox proportional hazard model. 
Multivariate analysis was used to adjust for age, histology, 
disease stage, use of bevacizumab, and type of platinum 
agent; genotypes were treated as indicator variables. All tests 
were two-sided and statistical significance was set at p < 0.05. 
Statistical analysis was carried out using SPSS software, 
version 11.0 (SPSS Inc., Chicago, IL).
RESULTS
Patient Characteristics
Clinical and pathological characteristics of 62 patients 
of the training set along with their treatment response are 
listed in Table 1. Median age was 57 years; 56.5% were men; 
and 84% of the patients had stage-IV disease. All patients 
received a platinum agent (cisplatin in 59, carboplatin in 
two and oxaliplatin in one) in addition to gemcitabine with 
(n = 13) or without (n = 49) bevacizumab in combination 
as their first-line chemotherapeutic agents. Ten patients, 
who received bevacizumab as maintenance therapy after 
completion of the first-lime chemotherapy, were excluded 
from the progression-free survival analysis of gemcitabine 
plus platinum chemotherapy. Forty-one of the 62 patients 
had tumors with known EGFR mutation status; 21 had 
activating EGFR mutations (deletions in exon 19 or L858R) 
and 20 had wild-type EGFR. All 62 patients received EGFR 
tyrosine kinase inhibitors as second- or third-line therapy. 
overall objective response rate to chemotherapy was 30.6%; 
PD rate was 14.6%. The median follow-up time was 22 months 
TABLE 1. Clinicopathologic Characteristics of Patients with 
Non–Small-Cell Lung Cancer
Training Set Validation Set
n = 62 n = 45
Age
 Median (range) 57 (36–78) 63 (43–83)
Gender, n (%)
 Male 35 (56.5) 26 (57.8)
 Female 27 (43.5) 19 (42.2)
Cell Type, n (%)
 Adenocarcinoma 52 (83.9) 38 (84.4)
 Squamous cell cancer 4 (6.5) 3 (6.7)
 others 6 (9.7) 4
EGFR Mutation Status
 Unknown 21 (34) N/A
 Wild-Type 20 (32) N/A
 Activating Mutation 21 (34) N/A
Stage, n (%)
 IIIB 10 (16) 10 (22.2)
 IV 52 (84) 35 (77.8)
Best Response, n (%)
 PR 19 (30.6) 23 (51.1)
 SD 34 (54.8) 9 (20)
 PD 9 (14.6) 13 (28.9)
Activating mutation, deletions in exon 19 or L858R;
EGFR, endothelial growth factor receptor; N/A, not available; PR, partial response; 
SD, stable disease; PD, progressive disease.
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(range, 4–65 months). The median progression-free 
survival time for first-line chemotherapy was 5.6 months 
(n = 52). There were 23 deaths with a median oS time of 
51 months.
Genotype Information and Treatment 
Response
The genotypic frequencies for each polymorphism are 
presented in Table 2. Although the A/A genotype has been 
termed the “variant” by convention, with regard to the RRM1 
G2464A polymorphism, in our study the A/A genotype was 
found in higher frequencies. RRM1 A2455G polymorphism 
was in Hardy-Weinberg disequilibrium among the eight SNPs 
studied. Genotype frequencies of the other six polymorphisms 
were consistent with previously reported studies. There was 
no significant association detected between genotype and sex, 
age, histology, or disease stage.
Patients were divided into groups based on treatment 
response as responders  or nonresponders (stable disease + 
PD). No significant correlation was observed between eight 
SNPs and objective response (Table 2). In multivariate logis-
tic regression analysis, patients receiving bevacizumab in 
addition to chemotherapy (gemcitabine/platinum) were more 
likely to be responders compared to those receiving only che-
motherapy (oR, 5.53; 95% CI, 1.50–20.35; p = 0.01) after 
adjusting for polymorphisms, age, histology, EGFR mutation 
status, disease stage, and type of platinum agent.
Polymorphisms and Survival
There was no significant difference in progression-free 
survival observed among the eight SNPs (Table 3). Table 4 
shows oS analysis data based on the eight polymorphisms 
examined. The wild-type genotype of XRCC1 399 (G/G) was 
associated with decreased oS in our analysis. The difference 
in the median survival times between patients carrying the 
wild-type genotype of XRCC1 399 (G/G, 22 months, 95% CI, 
10–34 months) and those carrying the heterozygous (A/G, 
not reached) and homozygous (A/A, not reached) variant 
genotype was statistically significant (log-rank test, p = 0.005, 
Fig. 1A.). In addition, there was a statistically significant dif-
ference in oS associated with ERCC2 312 polymorphism. 
The median survival times of the wild-type genotype ERCC2 
312 (G/G) and heterozygous variant genotype (A/G) were 51 
(95% CI, 19–82) and 10 months, respectively (log-rank test, 
p < 0.001, Fig. 1B.).
In the multivariate Cox proportional hazards model, 
after adjusting for age, histology, disease stage, EGFR muta-
tion status, use of bevacizumab, and type of platinum agent, 
and polymorphic genotype as an indicator variable, we found 
a significant effect of XRCC1 399 and ERCC2 312 poly-
morphisms on patients’ oS. The HR was significantly lower 
for patients with XRCC1 399 heterozygous variant geno-
type (A/G) compared with wild-type genotype (G/G) (HR, 
0.292; 95% CI, 0.116–0.734, p = 0.009), whereas homozy-
gotes (A/A) showed no significance (HR, 0.276; 95% 
CI, 0.036–2.134, p = 0.217). Because there were only five 
TABLE 2. Genotype Frequencies and Response to Gemcitabine/Platinum Chemotherapy 
According to Genotype
Gene Genotype
No. of Patients (%)
p ValueFrequencies Responders PR Nonresponders SD + PD
ERCC1 Asn118Asn C/C 36 (58) 12 (33) 24 (67) 0.429
C/T 22 (35) 7 (32) 15 (68)
T/T 4 (7) 0 (0) 4 (100)
ERCC1 C8092A C/C 21 (35) 8 (38) 13 (62) 0.720
C/A 30 (50) 8 (27) 22 (73)
A/A 9 (15) 3 (33) 6 (67)
ERCC2 Lys751Gln A/A 57 (92) 19 (33) 38 (67) 0.312
A/C 5 (8) 0 (0) 5 (100)
ERCC2 Asp312Asn G/G 60 (97) 18 (30) 42 (70) 0.522
G/A 2 (3) 1 (50) 1 (50)
XRCC1 Arg399Gln G/G 26 (43) 9 (35) 17 (65) 0.919
G/A 31 (48) 9 (29) 22 (71)
A/A 5 (9) 1 (20) 4 (80)
XRCC3 Thr241Met C/C 59 (97) 18 (31) 41 (69) 1.000
C/T 3 (3) 1 (33) 2 (67)
RRM1 A2455G A/A 16 (26) 3 (19) 13 (81) 0.335
A/G 40 (65) 15 (38) 25 (62)
G/G 6 (9) 1 (17) 5 (83)
RRM1 G2464A G/G 4 (6) 0 (0) 4 (100) 0.469
A/G 31 (50) 11 (35) 20 (65)
A/A 27 (44) 8 (30) 19 (70)
PR, partial response; SD, stable disease; PD, progressive disease.
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TABLE 4. Overall Survival in NSCLC Patients Treated with Gemcitabine/Platinum Chemotherapy 
According to Genotype: Univariate Survival Analysis
Gene Genotype
No. of 
Patients
Median (m) 
(95%CI)
Log-Rank 
p Value
Univariate Hazard Ratio 
(95%CI) p Value
ERCC1 Asn118Asn C/C 36 51 (18–83) 0.682 0.617 (0.174–2.183) 0.453
C/T 22 NR 0.554 (0.142–2.164) 0.396
T/T 4 22 (4–39) 1.0 (Reference) 0.688
ERCC1 C8092A C/C 21 51 (13–88) 0.384 1.0 (Reference) 0.408
C/A 30 NR 0.659 (0.253–1.718) 0.394
A/A 9 35 (9–56) 1.590 (0.525–4.810) 0.412
ERCC2 Lys751Gln A/A 57 51 (19–82) 0.901 1.0 (Reference)
A/C 5 NR 0.912 (0.213–3.907) 0.901
ERCC2 Asp312Asn G/G 60 51 (19–82) <0.001 1.0 (Reference)
G/A 2 10 24.964 (4.087–152.48) <0.001
XRCC1 Arg399Gln G/G 26 22 (10–34) 0.005 1.0 (Reference) 0.003
G/A 31 NR 0.263 (0.107–0.644) 0.003
A/A 5 NR 0.246 (0.032–1.879) 0.176
XRCC3 Thr241Met C/C 59 51 (19–82) 0.257 22.260 (0.006–80659) 0.458
C/T 3 NR 1.0 (Reference)
RRM1 A2455G A/A 16 51 (20–81) 0.739 0.716 (0.137–3.751) 0.692
A/G 40 32 1.064 (0.242–4.676) 0.935
G/G 6 29 1.0 (Reference) 0.742
RRM1 G2464A G/G 4 NR 0.685 1.0 (Reference) 0.701
A/G 31 32 2.394 (0.310–18.462) 0.402
A/A 27 51 2.345 (0.294–18.676) 0.421
CI, confidence interval; NR, not reached.
TABLE 3. Progression-Free Survival in NSCLC Patients 
Treated with Gemcitabine/Platinum Chemotherapy According 
to Genotype
Gene Genotype
No. of 
Patients
Median (month) 
(95% CI)
Log-Rank 
p Value
ERCC1 
Asn118Asn
C/C 30 5.1 (3.7–6.5) 0.357
C/T 18 5.8 (4.9–6.8)
T/T 4 3.3 (0–9.3)
ERCC1 C8092A
C/C 16 5.6 (4.4–6.8) 0.752
C/A 25 5.1 (2.6–7.6)
A/A 8 5.7 (3.7–7.7)
ERCC2 Lys751Gln
A/A 47 5.6 (4.8–6.4) 0.428
A/C 5 4.0 (3.2–4.7)
ERCC2 Asp312Asn
G/G 51 5.6 (4.7–6.5) 0.482
G/A 1 4.7
XRCC1 Arg399Gln
G/G 26 5.8 (4.2–7.4) 0.672
G/A 28 5.1 (3.3–7.0)
A/A 5 5.1 (3.1–7.2)
XRCC3 Thr241Met
C/C 49 5.6 (4.8–6.4) 0.897
C/T 3 7.4 (0.1–14.7)
RRM1 A2455G
A/A 15 7.3 (4.0–10.6) 0.251
A/G 32 5.6 (4.6–6.6)
G/G 5 4.3 (4.0–4.6)
RRM1 G2464A
G/G 4 8.4 (1.5–15.4) 0.388
A/G 25 5.1 (3.5–6.8)
A/A 23 6.6 (5.4–7.8)
NSCLC, non–small-cell lung cancer.
patients carrying the XRCC1 399 homozygous variant geno-
type, we considered patients with homozygous and heterozy-
gous variant genotypes as individuals carrying at least one 
A allele (G/A+A/A) of XRCC1 399 genotypes. The analysis 
showed a statistically significant better survival of variant gen-
otypes (G/A+A/A) when compared with the wild-type geno-
type (G/G) (HR, 0.290; 95% CI, 0.12–0.705, p = 0.006). For 
ERCC2 312 polymorphism, the HR was significantly higher 
for patients with ERCC2 312 heterozygous variant genotype 
(G/A) compared with wild-type genotype (G/G) (HR, 14.04; 
95% CI, 2.253–87.513, p = 0.005).
Validation Set
The characteristics of the 45 NSCLC patients in the 
validation set are listed in Table 1. Median age was 63 years; 
57.8% were men; and 77.8% of patients had stage-IV disease. 
overall objective response rate to chemotherapy was 50.1%; 
PD rate was 28.9%. They also received EGFR tyrosine kinase 
inhibitors as second- or third-line therapy. The median follow-
up time was 34 months (range, 2–127 months). The median 
progression-free survival time for first-line chemotherapy was 
7 months. There were 40 deaths with a median oS time of 34 
months. We tested only XRCC1 399 and ERCC2 312 geno-
typing for this validation set. No significant correlation was 
observed between these two SNPs and objective response, 
and there was no significant difference in progression-free 
survival observed according to these two SNPs. The wild-type 
genotype of XRCC1 399 (G/G) was associated with decreased 
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oS in the validation set. The difference in the median sur-
vival times between patients carrying the wild-type genotype 
of XRCC1 399 (G/G, 29 months, 95% CI, 20–38 months) and 
those carrying at least one A allele (G/A+A/A) of XRCC1 399 
genotypes (45 months, 95% CI, 36–54 months) was statisti-
cally significant (log-rank test, p = 0.023, Fig. 2A.). However, 
there was no statistically significant difference in oS asso-
ciated with ERCC2 312 polymorphism in the validation set 
(log-rank test, p = 0.787, Fig. 2B.). In the multivariate Cox 
proportional hazards model, after adjusting for age, histol-
ogy, disease stage, and polymorphic genotype as an indica-
tor variable, we only found one significant effect of XRCC1 
399 polymorphisms on patients’ oS in the validation set. 
The analysis showed a statistically significant better survival 
of variant genotypes (G/A+A/A) when compared with the 
wild-type genotype (G/G) (HR, 0.474; 95% CI, 0.245–0.915, 
p = 0.026).
DISCUSSION
The study of SNP provides opportunity in seeking for 
suitable markers to predict treatment outcome with cytotoxic 
chemotherapy.6 In this study, we evaluated the role of eight 
DNA-repair gene polymorphisms in the treatment outcome of 
gemcitabine/platinum-treated advanced NSCLC patients. our 
FIGURE 1. A, Kaplan-Meier estimates of the overall survival 
of 62 NSCLC patients in the training set according to XRCC1 
399 polymorphism (p = 0.005, log-rank test). B, Kaplan-Meier 
estimates of the overall survival of 62 NSCLC patients in  
the training set according to ERCC2 312 polymorphism  
(p < 0.001, log-rank test). NSCLC, non–small-cell lung cancer; 
ERCC2, excision repair cross-complementing group 2.
FIGURE 2. A, Kaplan-Meier estimates of the overall  
survival of 45 NSCLC patients in the validation set according 
to XRCC1 399 polymorphism (p = 0.023, log-rank test).  
B, Kaplan-Meier estimates of the overall survival of 45 NSCLC 
patients in the validation set according to ERCC2 312  
polymorphism (p = 0.787, Log-rank test). NSCLC, non– 
small-cell lung cancer; ERCC2, excision repair cross- 
complementing group 2.
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data showed that there are survival differences according to 
the XRCC1 Arg399Gln polymorphism in the training set and 
the validation set. Patients with wild-type XRCC1 399 (G/G) 
had significantly shorter oS than those harboring non–wild-
type XRCC1 399 (A/G+A/A). However, patients with wild-
type ERCC2 312 (G/G) had significantly longer oS than those 
harboring non–wild-type ERCC2 312 (A/G) only in the train-
ing set. The other polymorphisms in our analysis showed no 
significant association with patient survival.
For individualized therapy, it is important to develop 
reliable biomarkers to select treatments for patients most 
likely to obtain benefit. Biomarkers predictive for survival 
benefit from a treatment are far more useful for guiding 
management than those that simply portend a favorable or 
unfavorable prognosis, independent of treatment. To further 
clarify whether the XRCC1 Arg399Gln polymorphism is of 
predictive or prognostic value on survival outcomes, a cohort 
of 47 patients with advanced NSCLC receiving non–gemcit-
abine-containing platinum doublets as their first-line chemo-
therapy at NTUH and TVGH were recruited for XRCC1 399 
genotyping (Supplemental Fig., Supplemental Digital Content 
1, http://links.lww.com/JTo/A283). There was no statistically 
significant difference in oS according to the XRCC1 399 poly-
morphism in this cohort (p = 0.155, log-rank test). The results 
suggested that the XRCC1 399 polymorphism could predict 
survival outcomes from gemcitabine/platinum doublet treat-
ment in advanced NSCLC patients, but lacks prognostic signif-
icance in non-gemcitabine platinum doublets treated patients.
The XRCC1 is a scaffold protein essential to the repair 
of base excision repair (BER) and single-strand breaks path-
ways.28 Impaired DNA-repair mechanisms resulting in the 
decreased removal of platinum-DNA adducts may improve sur-
vival in patients already diagnosed with cancer, when treated 
with a platinum agent. on the contrary, decreased DNA repair 
may increase the risk of developing cancer.8 Polymorphisms in 
DNA-repair genes may consequently contribute to interindi-
vidual diversity in DNA-repair capacity; however, the results 
from several studies have been generally inconsistent.29 More 
than 60 SNPs have been identified in the XRCC1 gene with 
the most extensively investigated coding region SNPs being 
Arg399Gln on exon 10 because of its location within the region 
of the BRCT1 binding domain. The effect of XRCC1 genotype 
on the ability of a cell to repair DNA damage has been evalu-
ated most commonly involving human lymphocytes challenged 
with a DNA-damaging agent with the repair ability compared 
across individuals having different genotypes.28 There are 
various lines of evidence showing that the variant genotype 
of XRCC1 399 can decrease repair capability using the above 
measurement. For example, removal of DNA adducts from two 
lymphoblast cell lines exposed to vinyl chloride metabolite 
had been evaluated and showed that the efficiency of repair of 
DNA adducts in the XRCC1 399 homozygous wild-type (G/G) 
cells was four times greater than the efficiency of repair in the 
homozygous variant (A/A) cells.30 In addition, Slyskova et al.31 
evaluated the removal of oxidative DNA damage after light 
irradiation and found a 3.4-fold deficit of homozygous variant 
(A/A) lymphocytes in DNA-repair capacity.
Epidemiological studies of polymorphisms in DNA-
repair genes can provide insight into the in vivo relationship 
between DNA-repair genes and lung cancer risk32 and treat-
ment outcome among lung cancer patients.11,12 Although lung 
cancer risk in the presence of the variant XRCC1 399 allele 
has not yielded significant associations in several studies, 
Kiyohara et al.33 found that the XRCC1 399 homozygous vari-
ant genotype (A/A) was associated with an increased risk of 
lung cancer among Asians (oR = 1.34, 95% CI = 1.16–1.54), 
but not of whites (oR = 0.94, 95% CI = 0.80–1.11) in a meta-
analysis. Many studies have shown the association between 
the XRCC1 399 polymorphism and the clinical outcome of 
NSCLC patients including treatment response and oS; how-
ever, the results have been inconsistent among studies. one 
study of platinum-treated patients found a positive effect of 
variant XRCC1 allele on survival outcome.34 on the con-
trary, Gurubhagavatula et al.23 reported that individuals with 
XRCC1 399 variant genotype were associated with shorter 
oS. Another study conducted by Sun et al.35 did not find a 
considerable association between XRCC1 399 polymorphism 
and treatment response in Chinese population. In the present 
study, we demonstrated that patients carrying at least one vari-
ant XRCC1 399 allele had better oS than those with wild-type 
XRCC1 399. our result was in agreement with the observation 
that impaired DNA-repair mechanisms may improve survival 
of NSCLC patients receiving platinum agents; because most 
of the studies indicated that a variant genotype of XRCC1 399 
can decrease DNA-repair capability.
Although the NER pathway is the major repair mech-
anisms for cisplatin-DNA adducts, the biologic effect of 
the XRCC1 protein on cisplatin drug action is indirect and 
may be through repair of other types of cisplatin-induce damage, 
such as double-strand breaks (DSBs)36 and ICL.37 XRCC1-DNA 
ligase III complex, which is involved in the BER pathway, had 
been proposed by Audebert et al.36 as a component of an alterna-
tive nonhomologous end-joining route of DNA DSBs. In addition, 
Zhu et al.38 found that poly (ADP-ribose) polymerase-1 , together 
with its partners XRCC1 and DNA ligase III, binds to a DNA 
duplex containing a platinum ICL. The above observation implies 
that XRCC1, a coordinator or BER and single-stand breaks repair, 
may be important for platinum DSBs and ICL repair.
The excision repair cross-complementing rodent 
repair deficiency, group 2 (ERCC2), also named the xero-
derma pigmentosum group D, belongs to the TFIIH complex 
and involves in NER and transcription. Two polymorphisms 
(ERCC2 312 and ERCC2 751), which are common and result 
in an amino-acid change, have mainly been investigated in 
relation to risk and clinical outcome of lung cancer.23,25,39 
It has been reported that ERCC2 312 variant alleles may 
induce higher level of DNA adducts, which is interpreted as 
a lower repair efficiency for the ERCC2 312 variant allele.40 
However, these findings remain a subject of controversy. 
Clarkson et al.41 used evolutional analysis and reported that 
polymorphisms of ERCC2 312 and ERCC2 751 are not well-
conserved among different organisms, and they strongly 
predicted that both polymorphisms are benign. Laine et 
al.42 also demonstrated that polymorphisms in the ERCC2 
gene using the baculovirus expression system to reconstitute 
recombinant TFIIH complexes in which the ERCC2 vari-
ants were introduced do not generate significant variations 
in NER efficiency.
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In the present study, we demonstrated that patients with 
wild-type ERCC2 312 (G/G) had significant longer oS than 
those harboring ERCC2 312 heterozygous variant genotype 
(G/A) in the training set. But there was no statistically signifi-
cant difference in oS associated with ERCC2 312 polymor-
phism in the validation set. The above results suggested that 
no convincing evidence supported the functional significance 
of ERCC2 312 polymorphism on DNA repair and clinical out-
comes of NSCLC patients.
Because of the relatively small patient population ana-
lyzed in the present study, its main limitation is that it can-
not be generalized in NSCLC patients. However, our study 
included a highly homogeneous cohort of gemcitabine/plat-
inum-treated advanced NSCLC patients among the Chinese 
population in Taiwan that might contribute to the relevant 
association of polymorphisms with clinical outcome.
In conclusion, our study, based on the analysis of eight 
polymorphisms in five DNA-repair genes, identified the 
XRCC1 399 polymorphism as a candidate for contributing 
interindividual difference in the oS of gemcitabine/platinum-
treated advanced NSCLC patients. our results suggest that 
polymorphisms of DNA-repair genes may play an important 
role in the outcome of advanced NSCLC patients, and imply 
the utility of polymorphism as predictive markers for treat-
ment outcome of chemotherapy.
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